ProMIS Other Current Assets from 2010 to 2025

PMN Stock  USD 0.70  0.01  1.41%   
ProMIS Neurosciences Other Current Assets yearly trend continues to be very stable with very little volatility. Other Current Assets are likely to grow to about 1.6 M this year. Other Current Assets is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. View All Fundamentals
 
Other Current Assets  
First Reported
2005-06-30
Previous Quarter
213 K
Current Value
2.3 M
Quarterly Volatility
523.2 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ProMIS Neurosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProMIS Neurosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 46.1 K, Total Revenue of 0.0 or Other Operating Expenses of 22.8 M, as well as many indicators such as Price To Sales Ratio of 5.1 K, Dividend Yield of 0.0 or PTB Ratio of 3.11. ProMIS financial statements analysis is a perfect complement when working with ProMIS Neurosciences Valuation or Volatility modules.
  
Check out the analysis of ProMIS Neurosciences Correlation against competitors.
To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.

Latest ProMIS Neurosciences' Other Current Assets Growth Pattern

Below is the plot of the Other Current Assets of ProMIS Neurosciences over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. ProMIS Neurosciences' Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProMIS Neurosciences' overall financial position and show how it may be relating to other accounts over time.
Other Current Assets10 Years Trend
Slightly volatile
   Other Current Assets   
321.135.688.925.1.3M1.5M1.6M-58%410%34%40%15%5%100%
       Timeline  

ProMIS Other Current Assets Regression Statistics

Arithmetic Mean505,265
Geometric Mean271,507
Coefficient Of Variation104.21
Mean Deviation427,802
Median321,807
Standard Deviation526,542
Sample Variance277.2B
Range1.5M
R-Value0.87
Mean Square Error74.3B
R-Squared0.75
Significance0.000015
Slope95,770
Total Sum of Squares4.2T

ProMIS Other Current Assets History

20251.6 M
20241.5 M
20231.3 M
2022925.1 K
2021688.6 K
2020135 K
2019321.8 K

About ProMIS Neurosciences Financial Statements

ProMIS Neurosciences investors utilize fundamental indicators, such as Other Current Assets, to predict how ProMIS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Other Current Assets1.5 M1.6 M

Pair Trading with ProMIS Neurosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.

Moving against ProMIS Stock

  0.53FENC Fennec PharmaceuticalsPairCorr
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether ProMIS Neurosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProMIS Neurosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Promis Neurosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Promis Neurosciences Stock:
Check out the analysis of ProMIS Neurosciences Correlation against competitors.
To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.04
Revenue Per Share
0.001
Return On Assets
(0.43)
Return On Equity
(0.08)
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

OPT
Opthea
3.55  -1.56  -30.53 
NAMSW
NewAmsterdam Pharma
12.36  1.76  16.60 
HLVX
Hillevax
1.78  0.03  1.71 
GANX
Gain Therapeutics
1.94  -0.01  -0.51 
NAMS
NewAmsterdam Pharma
21.50  1.23  6.07 
IVA
Inventiva Sa
2.82  -0.14  -4.73 
CNTA
Centessa Pharmaceuticals
16.33  1.29  8.58 
GLUE
Monte Rosa Therapeutics
5.55  0.05  0.91 
CUE
Cue Biopharma
1.17  -0.03  -2.5 
CMPX
Compass Therapeutics
2.78  0.05  1.83 
ZHCLF
Zenith Capital Corp
0.10  0.1  99,900 
BIVI
Biovie Inc
1.19  0.01  0.85 
BIOAF
biOasis Technologies
0.0004  0.0003  300.00 
HOPHF
Hemogenyx Pharmaceuticals
1.24  0.00  0.00 
FENC
Fennec Pharmaceuticals
6.73  -0.04  -0.59 
CGEM
Cullinan Oncology LLC
8.00  -0.49  -5.77 
INAB
In8bio Inc
0.26  -0.01  -3.7 
STRO
Sutro Biopharma
1.42  -0.02  -1.39 
News Freq…Investor S…